We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Huperzine for Cognitive and Functional Impairment in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00963846
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : March 1, 2013
Yale University
Information provided by (Responsible Party):
Scott Woods, MD, Biomedisyn Corporation

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : December 2012
  Study Completion Date : December 2012

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 8, 2016 October 27, 2016